Titre
High prevalence of secondary resistance mutations in Venezuelan HIV-1 isolates.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Dieudonne, M.
Auteure/Auteur
Garzaro, D.
Auteure/Auteur
Torres, J.
Auteure/Auteur
Naranjo, L.
Auteure/Auteur
Suárez, J.A.
Auteure/Auteur
Castro, J.
Auteure/Auteur
Martínez, N.
Auteure/Auteur
Castro, E.
Auteure/Auteur
Berrueta, L.
Auteure/Auteur
Salmen, S.
Auteure/Auteur
Devesa, M.
Auteure/Auteur
Rangel, H.R.
Auteure/Auteur
Pujol, F.H.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0535-5133
Statut éditorial
Publié
Date de publication
2006-03
Volume
47
Numéro
1
Première page
27
Dernière page/numéro d’article
34
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Publication Status: ppublish
Résumé
The genetic variability was studied in HIV-1 from Venezuelan patients with and without treatment, in order to evaluate the presence of polymorphisms and drug resistance mutations. Proviral DNA from peripheral blood mononuclear cells or viral RNA from plasma was extracted from the blood of 30 patients. Two regions from the polymerase gene, protease (Pr) and reverse transcriptase (RT) and one genomic fragment from the envelope (Env) gene were amplified and sequenced. All HIV-1 samples analyzed were classified as subtype B, without evidence of recombination. Although no primary protease mutations were detected, a high frequency of secondary mutations (86%, 19/22), associated to restoration of viral replicative fitness, was observed in strains circulating both in treated and non-treated patients. Resistance mutations to nucleoside RT inhibitors (NRTI) and non-nucleoside RT inhibitors (NNRTI) were detected in 35% (6/17) and 12% (2/17) of the viruses circulating in treated patients, respectively. Resistance mutations were also present in the virus infecting one antiretroviral naive individual (7.7%), suggesting that local screening for resistant mutation in naive patient might be important to minimize therapy failure. Future studies are warranted to assess the role of secondary mutation in the success of viral infection.
PID Serval
serval:BIB_5F97D511348E
PMID
Date de création
2017-05-04T14:49:37.923Z
Date de création dans IRIS
2025-05-20T18:59:25Z
Fichier(s)![Vignette d'image]()
En cours de chargement...
Nom
16562642.pdf
Version du manuscrit
preprint
Taille
509.41 KB
Format
Adobe PDF
PID Serval
serval:BIB_5F97D511348E.P001
URN
urn:nbn:ch:serval-BIB_5F97D511348E5
Somme de contrôle
(MD5):4b2401ada9055fd27126e8c1fff7ecef